Healthcare Industry News: C.R. Bard
News Release - October 20, 2016
Corindus Vascular Robotics Appoints Jeff Lemaster Chief Commercial OfficerWALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, today announced the appointment of Jeff Lemaster as Chief Commercial Officer.
Mr. Lemaster brings 20 years of commercial sales and marketing experience in the cardiovascular medical device industry to Corindus and has extensive global new product launch experience in the areas of interventional cardiology and peripheral. He most recently served as Global Vice President, Marketing of C.R. Bard, Inc. [NYSE: BCR], a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies. He has a proven track record of commercial success having held senior sales and marketing leadership positions at C.R. Bard, ACIST Medical Systems and Boston Scientific Corporation (BSX).
As Chief Commercial Officer at Corindus, Mr. Lemaster will lead and execute revenue and commercial strategy to drive growth and market adoption globally.
"I am delighted to welcome Jeff to Corindus, and we look forward to his future contributions. His extensive commercial experience, particularly in the interventional and peripheral arena, will enable us to build and sustain strong robotic programs that benefit our customers and their patients," said Corindus CEO, Mark J. Toland.
"I look forward to working with the Corindus team and the broader interventional community to build robotic programs that transform the way we treat patients while protecting cath lab teams," said Mr. Lemaster.
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to complex, radial, coronary and peripheral procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.
Source: Corindus Vascular Robotics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.